Journal of Cancer Research and Treatment
ISSN (Print): 2374-1996 ISSN (Online): 2374-2003 Website: http://www.sciepub.com/journal/jcrt Editor-in-chief: Jean Rommelaere
Open Access
Journal Browser
Go
Journal of Cancer Research and Treatment. 2017, 5(4), 113-119
DOI: 10.12691/jcrt-5-4-2
Open AccessArticle

Impact of DNA Repair Genes Polymorphisms on Incidence and Prognosis of Breast Cancer in an Egyptian Cohort

Ebtsam R. Zaher1, , Mahmoud A. Hemida2 and Mostafa Al-Naggar3

1Radiation Sciences Department, Medical Research Institute, Alexandria University, Alexandria, Egypt

2Experimental and Clinical Surgery Department, Medical Research Institute, Alexandria University, Alexandria, Egypt

3Cancer Management and Research Department, Medical Research Institute, Alexandria Universit, Alexandria, Egypt

Pub. Date: November 25, 2017

Cite this paper:
Ebtsam R. Zaher, Mahmoud A. Hemida and Mostafa Al-Naggar. Impact of DNA Repair Genes Polymorphisms on Incidence and Prognosis of Breast Cancer in an Egyptian Cohort. Journal of Cancer Research and Treatment. 2017; 5(4):113-119. doi: 10.12691/jcrt-5-4-2

Abstract

Background: Sporadic breast cancer might be caused by low-penetrance genes, including genes constituting the DNA repair pathways. Defective DNA repair is a common imprint of cancer that promotes the accretion of DNA errors and genomic instability. The clustering of damage in DNA may stimulate breast carcinogenesis. Aims: The goal of the study is to evaluate the role of single nucleotide polymorphisms in DNA repair genes XRCC1 Arg399Gln, XPD Lys751Gln, RAD51 G135C and XRCC3 Thr241Met as genetic indicators of susceptibility to breast cancer and to evaluate their role in treatment outcome. Methodology: The study included 248 females diagnosed with primary breast cancer and 232 normal healthy females. Patients were clinically followed up for 5 years after completing chemotherapy. Genomic DNA was isolated and the four polymorphisms under investigation were assessed by PCR-RFLP technique. Findings: XRCC1 399Gln, XPD 751Gln and XRCC3 241Met alleles were significantly associated with breast cancer risk (OR = 2.63, 2.17 and 3.21; respectively), with carriers having lower disease free survival (DSF). When grouping patients based on the number of affected genotypes they carry, DFS decreased as the number of affected genotypes increased (Paccum<0.001), patients carrying three (HR=4.74, p<0.001) or two (HR=3.35, p=0.005) affected genotypes had significantly worse DFS compared with those carrying zero (reference) or one (HR=1.37, p=0.093) affected genotype. RAD51 5’UTR G135C polymorphism was not associated with breast cancer risk (p=0.932) or with DFS. Conclusion: XRCC1 Arg399Gln, XPD Lys751Gln and XRCC3 Thr241Met polymorphisms may take a significant part in sporadic breast cancer as risk factors and in prognosis, where patients carrying XRCC1 Arg/Arg, XPD Lys/Lys and XRCC3 Thr/Thr genotypes had significantly diminished risk for breast cancer and higher DFS. DFS decreased as the number of affected genotypes increased. But RAD51 5'UTR G135C polymorphism did not associate with either risk or prognosis of breast cancer.

Keywords:
breast neoplasm DNA repair gene single nucleotide polymorphism XRCC1 XRCC3 XPD

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Ibrahim, A.S., Khaled, H.M., Mikhail, N.H., Baraka, H. and Kamel, H. “Cancer Incidence in Egypt: Results of the National Population-Based Cancer Registry Program” Journal of Cancer Epidemiology 2014; Article ID: 437971, 2014.
 
[2]  Dumitrescu, R.G. and Cotarla, I., “Understanding breast cancer risk -- where do we stand in 2005?” Journal of Cellular and Molecular Medicine, 9 (1). 208-221. Jan-Mar 2005.
 
[3]  Jackson, S.P. and Bartek, J., “The DNA-Damage response in human biology and disease” Nature, 461 (7267). 1071-1078. October 2009.
 
[4]  Wood, R.D., Mitchell, M., Sgouros, J. and Lindahl, T., “Human DNA repair genes” Science, 291 (5507). 1284-1289. February 2001.
 
[5]  Lotkionov, A., “Common gene polymorphisms, cancer progression and prognosis” Cancer Letters, 208 (1). 1-33. May 2004.
 
[6]  Sainsbury, R, Breast. In, Kirk, R.M and Winslet, M.C, General Surgical Operations, 5th ed. Churchill Livingstone Elsevier, 2006, 370-383.
 
[7]  Haskell, C.M, Breast cancer. In, Casciato, D.A, Manual of Clinical Oncology, 6th ed. Lippincott Williams and Wilkins, USA, 2004, 218-237.
 
[8]  Barrdahl, M., Canzian, F., Lindström, S., Shui, I., Black, A., Hoover, R.N., Ziegler, R.G., Buring, J.E., Chanock, S.J., Diver, W.R., Gapstur, S.M., Gaudet, M.M., Giles, G.G., Haiman, C., Henderson, B.E., Hankinson, S., Hunter, D.J., Joshi, A.D., Kraft, P., Lee, I., LeMarchand, L., Milne, R.L., Southey, M.C., Willett, W., Gunter, M., Panico, S., Sund, M., Weiderpass, E., Sánchez, M.J., Overvad, K., Dossus, L., Peeters, P.H., Khaw, K.T., Trichopoulos, D., Kaaks, R. and Campa, D., “Association of breast cancer risk loci with breast cancer survival” International Journal of Cancer, 137(12). 2837-2845. December 2015.
 
[9]  London, R.E., “The structural basis of XRCC1-mediated DNA repair” DNA Repair (Amst), 30: 90-103. June 2015.
 
[10]  Hung, R.J., Hall, J., Brennan, P. and Boffetta, P., “Genetic polymorphisms in the base excision repair pathway and cancer risk: a HuGE review” American Journal of Epidemiology, 162 (10). 925-942. November 2005.
 
[11]  Sanjari Moghaddam, A., Nazarzadeh, M., Sanjari Moghaddam, H., Bidel, Z., Keramatinia, A., Darvish, H. and Mosavi-Jarrahi, A., “XRCC1 Gene Polymorphisms and Breast Cancer Risk: A Systematic Review and Meta-Analysis Study” Asian Pacific Journal of Cancer Prevention, 17 (S3). 323-330. June 2016.
 
[12]  Chen, X.P., Wen, H.F., Zhang, F., Xu, W.H., Ma, Z.C., Fu, S.M., “Assessment of the Link between XRCC1 Arg399Gln Polymorphism and Breast Cancer: a Meta-Analysis in a Single Ethnic Group” Clinical Laboratory, 63 (4). 725-731. 2017.
 
[13]  Bu, T., Liu, L., Sun, Y., Zhao, L., Peng, Y., Zhou, S., Li, L., Chen, S. and Gao, Y., “XRCC1 Arg399Gln polymorphism confers risk of breast cancer in American population: a meta-analysis of 10846 cases and 11723 controls” PLoS One, 9 (1). Article ID: e86086. 2014.
 
[14]  Yi, L., Xiao-Feng, H., Yun-Tao, L., Hao, L., Ye, S. and Song-Tao, Q., “Association between the XRCC1 Arg399Gln polymorphism and risk of cancer: evidence from 297 case-control studies” PLoS One; 8 (10). Article ID: e78071. 2013.
 
[15]  Patel, A.V., Calle, E.E., Pavluck, A.L., Feigelson, H.S., Thun, M.J. and Rodriguez, C., “A prospective study of XRCC1 (X-ray cross-complementing group 1) polymorphisms and breast cancer risk” Breast Cancer Research, 7. Article ID: R1168. November 2005.
 
[16]  Zhang, H., Ma, L., Guo, W.Z., Liu, G. and Ma, Y., “The ERCC2 gene K751Q polymorphism contributes to cancer susceptibility in Chinese population: a meta-analysis of 40827 subjects” International journal of clinical and experimental medicine, 9 (2). 3292-3303. February 2016.
 
[17]  Wu, K.G., He, X.F., Li, Y.H., Xie, W.B. and Huang, X., “Association between the XPD/ERCC2 Lys751Gln polymorphism and risk of cancer: evidence from 224 case-control studies” Tumour Biology; 35 (11). 11243-11259. November 2014.
 
[18]  Alanazi, M., Pathan, A.A.K., Ajaj, S.A., Khan, W., Shaik, J.B., Al Tassan, N. and Parine, N.R., “DNA Repair Genes XRCC1, XRCC3, XPD, and OGG1 Polymorphisms among the Central Region Population of Saudi Arabia” Biological Research, 46 (2). 161-167. 2013.
 
[19]  Yan, Y., Liang, H., Light, M., Li, T., Deng, Y., Li, M., Li, S. and Qin, X., “XPD Asp312Asn and Lys751Gln polymorphisms and breast cancer susceptibility: a meta-analysis” Tumour Biology, 35 (3). 1907-1915. March 2014.
 
[20]  Mao, C.F., Qian, W.Y., Wu, J.Z., Sun, D.W. and Tang, J.H., “The XRCC3 Thr241Met Polymorphism and Breast Cancer Risk: an Updated Meta-analysis” Asian Pacific Journal of Cancer Prevention, 15 (16). 6613-6618. December 2014.
 
[21]  Chai, F., Liang, Y., Chen, L., Zhang, F. and Jiang, J., “Association Between XRCC3 Thr241Met Polymorphism and Risk of Breast Cancer: Meta-Analysis of 23 Case-Control Studies” Medical Science Monitor, 21. 3231-40. October 2015.
 
[22]  Economopoulos, K.P. and Sergentanis, T.N., “XRCC3 Thr241Met polymorphism and breast cancer risk: a meta-analysis” Breast Cancer Research and Treatment; 121 (2). 439-443. June 2010.
 
[23]  Gao, L.B., Pan, X.M., Li, L.J., Liang, W.B., Zhu, Y., Zhang, L.S., Wei, Y.G., Tang, M. and Zhang, L., “RAD51 135G/C polymorphism and breast cancer risk: a meta-analysis from 21 studies” Breast Cancer Research and Treatment, 125 (3). 827-835. February 2011.
 
[24]  Yu, K.D., Yang, C., Fan, L., Chen, A.X. and Shao, Z.M., “RAD51 135G>C does not modify breast cancer risk in non-BRCA1/2 mutation carriers: evidence from a meta-analysis of 12 studies” Breast Cancer Research and Treatment, 126 (2). 365-371. April 2011.
 
[25]  Sekhar, D., Pooja, S., Kumar, S. and Rajender, S., “RAD51 135G>C substitution increases breast cancer risk in an ethnic-specific manner: a meta-analysis on 21,236 cases and 19,407 controls” Scientific Reports, 5. Article ID: 11588. June 2015.
 
[26]  Sun, H., Bai, J., Chen, F., Jin, Y., Yu, Y., Jin, L. and Fu, S., “RAD51 G135C polymorphism is associated with breast cancer susceptibility: a meta-analysis involving 22,399 subjects” Breast Cancer Research and Treatment, 125 (1). 157-161. January 2011
 
[27]  Li, W., Liu, K., Song, J.S., Song, R. and Liu, Z.L., “Association between RAD51 polymorphism and breast cancer susceptibility: a meta-analysis” International journal of clinical and experimental medicine, 8 (2). 2326-2333. February 2015.
 
[28]  Bewick, M.A., Conlon, M.S.C. and Lafrenie, R.M., “Polymorphisms in XRCC1, XRCC3, and CCND1 and survival after treatment for metastatic Breast Cancer” Journal of Clinical Oncology, 24 (36). 5645-5651. December 2006.
 
[29]  Castro, E., Olmos, D., Garcia, A., Cruz, J.J. and González-Sarmiento, R., “Role of XRCC3, XRCC1 and XPD single-nucleotide polymorphisms in survival outcomes following adjuvant chemotherapy in early stage breast cancer patients” Clinical and Translational Oncology, 16 (2). 158-65. February 2014.
 
[30]  Matullo, G., Dunning, A.M., Guarrera, S., Baynes, C., Polidoro, S., Garte, S., Autrup, H., Malaveille, C., Peluso, M., Airoldi, L., Veglia, F., Gormally, E., Hoek, G., Krzyzanowski, M., Overvad, K., Raaschou-Nielsen, O., Clavel-Chapelon, F., Linseisen, J., Boeing, H., Trichopoulou, A., Palli, D., Krogh, V., Tumino, R., Panico, S., Bueno-De-Mesquita, H.B., Peeters, P.H., Lund, E., Pera, G., Martinez, C., Dorronsoro, M., Barricarte, A., Tormo, M.J., Quiros, J.R., Day, N.E., Key, T.J., Saracci, R., Kaaks, R., Riboli, E. and Vineis, P., “DNA repair polymorphisms and cancer risk in non-smokers in a cohort study” Carcinogenesis, 27 (5). 997-1007. May 2006.